FDA Reportedly Expands Ryzumvi Approval to Treat Age-Related Near Vision Loss
Nightly phentolamine drops improved near vision in a phase III trial, offering another option for age-related focusing loss.
Summary
Presbyopia, the age-related loss of near focusing ability, may have another prescription treatment option. MedPage Today reports that the FDA expanded approval of phentolamine eye drops, sold as Ryzumvi, to treat the condition. In a trial of 569 adults ages 40–64, 27% using nightly drops gained at least three lines of near vision while maintaining distance vision within the study’s limit, compared with 12% using placebo. The drops reduce pupil size rather than reverse aging of the eye’s lens. Common side effects included redness and irritation. An eye care professional can help determine suitability, especially for contact lens wearers or adults with eye inflammation. Important caveats remain: the report relies partly on company statements, and its headline references twelve weeks while the detailed results describe day eight.
Detailed Summary
Presbyopia, the gradual loss of near focusing ability with age, can make reading and everyday tasks harder. According to MedPage Today, the FDA expanded approval of phentolamine eye drops marketed as Ryzumvi to treat this condition. The treatment aims to improve close vision without substantially reducing distance vision, offering another prescription option for adults experiencing this common consequence of aging.
The strongest numerical evidence described comes from VEGA-3, a trial involving 569 adults ages 40 to 64 with reduced near vision. Participants received nightly phentolamine drops or placebo. On day eight, twelve hours after dosing, 27% versus 12% gained at least three lines on a near vision chart while losing fewer than five letters on a corrected distance vision test.
That represents a 15 percentage point difference, although most treated participants did not meet this response threshold. A significant difference was also reported within one hour after dosing. Phentolamine reduces pupil size by blocking sympathetic nerve signals rather than acting on the focusing muscle. This approach improves optical conditions for near vision rather than reversing the underlying aging of lenses.
Side effects were mostly mild and temporary. Reported rates included eye redness in 26%, irritation where drops were applied in 15%, altered taste in 5.9%, eye irritation in 5.6%, and headache in 2.6%. The article advises against use with active eye inflammation and recommends removing contact lenses before dosing, then waiting ten minutes before reinserting them as the manufacturer directs.
An eye care professional can assess whether this option fits an individual's vision needs and eye health. However, this is a news report drawing partly on company statements, not a full trial publication. Its headline references twelve weeks, while the detailed efficacy results concern day eight. Verify the official prescribing information, complete trial results, durability, and longer term safety data.
Key Findings
- In VEGA-3, 27% receiving phentolamine met the combined near-vision improvement and distance-vision preservation endpoint, versus 12% receiving placebo.
- The primary result was measured on day eight, twelve hours after dosing; it does not establish long-term benefit.
- Phentolamine reduces pupil size to improve near vision; it does not reverse age-related changes in the lens.
- Reported side effects included eye redness in 26% and irritation at the application site in 15%.
- Discuss suitability with an eye care professional; the article advises avoiding use during active eye inflammation.
Methodology
This is a medical news report from MedPage Today, drawing partly on manufacturer statements and reported phase III trial findings. The main numerical evidence comes from VEGA-3, a randomized, placebo-controlled trial involving 569 adults; VEGA-2 evaluated phentolamine combined with pilocarpine rather than phentolamine alone.
Study Limitations
The supplied report does not provide full trial methods, placebo adverse-event rates, or detailed long-term outcomes, and the reported approval has not been independently verified here. Its headline references twelve weeks, but the detailed primary endpoint concerns day eight; verify the FDA label and primary trial publications before drawing conclusions about durability or broader applicability.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: